[HTML][HTML] A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non …
B Pierre, B Elisabetta, R Vlad, HM Philippe… - Contemporary Clinical …, 2020 - Elsevier
Background Non-alcoholic steatohepatitis (NASH), a multifactorial disease, can progress to
hepatic fibrosis and cirrhosis. The Peroxysomal Proliferator-Activated Receptors, PPARα …
hepatic fibrosis and cirrhosis. The Peroxysomal Proliferator-Activated Receptors, PPARα …
A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non …
B Pierre, B Elisabetta, R Vlad… - Contemporary …, 2020 - hal.sorbonne-universite.fr
Background Non-alcoholic steatohepatitis (NASH), a multifactorial disease, can progress to
hepatic fibrosis and cirrhosis. The Peroxysomal Proliferator-Activated Receptors, PPARα …
hepatic fibrosis and cirrhosis. The Peroxysomal Proliferator-Activated Receptors, PPARα …
[引用][C] A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non …
M Francque Sven, B Pierre… - Contemporary Clinical …, 2020 - cir.nii.ac.jp
A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept,
24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis …
24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis …
A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non …
B Pierre, B Elisabetta, R Vlad, HM Philippe, S Bruno… - 2020 - pubmed.ncbi.nlm.nih.gov
Background Non-alcoholic steatohepatitis (NASH), a multifactorial disease, can progress to
hepatic fibrosis and cirrhosis. The Peroxysomal Proliferator-Activated Receptors, PPARα …
hepatic fibrosis and cirrhosis. The Peroxysomal Proliferator-Activated Receptors, PPARα …
A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non …
SM Francque, P Bedossa… - … clinical trials.-New …, 2020 - repository.uantwerpen.be
Background Non-alcoholic steatohepatitis (NASH), a multifactorial disease, can progress to
hepatic fibrosis and cirrhosis. The Peroxysomal Proliferator-Activated Receptors, PPARα …
hepatic fibrosis and cirrhosis. The Peroxysomal Proliferator-Activated Receptors, PPARα …
A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non …
MF Sven, B Pierre, FA Manal, MA Quentin… - Contemporary …, 2020 - europepmc.org
Background Non-alcoholic steatohepatitis (NASH), a multifactorial disease, can progress to
hepatic fibrosis and cirrhosis. The Peroxysomal Proliferator-Activated Receptors, PPARα …
hepatic fibrosis and cirrhosis. The Peroxysomal Proliferator-Activated Receptors, PPARα …
[PDF][PDF] A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non …
B Elisabetta, R Vlad, HM Philippe, S Bruno… - Contemporary Clinical …, 2020 - apef.com.pt
Background Non-alcoholic steatohepatitis (NASH), a multifactorial disease, can progress to
hepatic fibrosis and cirrhosis. The Peroxysomal Proliferator-Activated Receptors, PPARα …
hepatic fibrosis and cirrhosis. The Peroxysomal Proliferator-Activated Receptors, PPARα …
[PDF][PDF] A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non …
M Francque Sven, B Pierre… - Contemporary …, 2020 - hal.sorbonne-universite.fr
Background Non-alcoholic steatohepatitis (NASH), a multifactorial disease, can progress to
hepatic fibrosis and cirrhosis. The Peroxysomal Proliferator-Activated Receptors, PPARα …
hepatic fibrosis and cirrhosis. The Peroxysomal Proliferator-Activated Receptors, PPARα …